Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Healthcare Dive23h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Investor's Business Daily on MSN21h
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.